Thank you, Madam Chair. I want to thank the witnesses for joining us today.
There is an old expression that says that one should never put the cart before the horse. The Gates Foundation conducted a study to assess vaccine manufacturing capability after announcing a competitive process and creating expectations. Expectations have been raised. Consortiums and universities bid on the contracts and are disappointed today to see that no new clinical research facility will be established. Therefore, I have to wonder why the Gates Foundations, before making any grand announcements and before launching a competition, did not seek assurances that this study on manufacturing capability could in fact be conducted and why it did not wait for a conclusive report to be drawn up and verify whether the vaccine that was already produced was effective.
That was my first question. I have another one that I will put to you right away. Then I will allow Dr. Bertozzi time to respond.
Dr. Cameron, when he testified last Tuesday, and Dr. Carver, speaking here today, both emphasized the need for quick action. They even made suggestions as to how federal government funds, and funds from the Bill & Melinda Gates Foundation, could be allocated for research on the treatment of HIV/AIDS. Like Dr. Engelhardt last Tuesday, you have not really told us today what you are planning for the future. I'm curious to know if you have already initiated any discussions to ascertain what the future holds.